Herbs (Global Traditional) · Traditional Chinese Medicine
Foti (Polygonum multiflorum) (Polygonum multiflorum)
Moderate Evidencebotanical3 PubMed Studies
Hermetica Superfood Encyclopedia
Foti (Polygonum multiflorum) is a traditional Chinese herb containing stilbene compounds like 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG). It works primarily through antioxidant pathways and hepatoprotective mechanisms involving NF-κB modulation.
Fo-ti (He shou wu) is the root and rhizome of Polygonum multiflorum (now Pleuropterus multiflorus), a perennial climbing vine native to central and southern China, Japan, Taiwan, and Vietnam. The roots are harvested from 3-4 year-old plants and used either unprocessed ('white' fo-ti) or processed by steaming in black soybean juice to create 'red' fo-ti.
High-quality human studies supporting fo-ti for any condition are lacking. Early research suggests a combination decoction containing fo-ti may help with hepatitis B-associated liver fibrosis, though the small amount of available research prevents firm conclusions. No PubMed-indexed randomized controlled trials or meta-analyses specific to fo-ti monotherapy were identified.
Traditional dosages include: capsules 560mg taken 2-3 times daily, raw herb powder 3g three times daily, dried herb 9-15g daily, or decoction using 1 teaspoon (5g) of root boiled in 1 cup water for 15 minutes. Consult a healthcare provider before starting any new supplement.
Foti (Polygonum multiflorum) root is not consumed as a macronutrient food source; its nutritional relevance lies primarily in its bioactive phytochemical content rather than conventional macronutrients or micronutrients. Dried root preparations contain approximately 70-80% carbohydrates by dry weight, primarily in the form of starch and structural polysaccharides (notably beta-1,3-glucans and rhamnogalacturonans at roughly 1.8-2.5% of dry weight). Protein content is low at approximately 3-5% dry weight, and fat content is negligible at under 1%. Crude fiber content is approximately 10-15% dry weight. The pharmacologically significant bioactive compounds include: (1) Stilbenes — trans-resveratrol (0.002-0.05% dry weight) and its glycoside piceid; (2) Stilbene glycosides — 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside (TSG), considered the primary marker compound, present at approximately 1.0-2.5% in raw root and up to 0.7-1.5% in processed (Zhi He Shou Wu) root per Chinese Pharmacopoeia standards (minimum 1.0% TSG required); (3) Anthraquinones — emodin (0.1-0.3% dry weight), physcion, rhein, and chrysophanol, which are substantially reduced upon processing with black bean decoction; (4) Tannins — predominantly condensed procyanidin B-type oligomers and polymeric tannins (5-8% dry weight), which contribute significantly to antioxidant activity; (5) Flavonoids — quercetin, kaempferol, and catechin derivatives at approximately 0.05-0.2% combined; (6) Phenolic acids — protocatechuic acid and gallic acid at trace to minor concentrations (0.01-0.05%). Processing (steaming with black bean liquid) significantly alters the phytochemical profile: free anthraquinone content drops by approximately 60-80%, reducing hepatotoxic risk, while TSG content may concentrate relatively. Mineral content includes modest levels of zinc (approximately 15-25 mg/kg dry weight), iron (approximately 80-120 mg/kg), calcium (approximately 400-600 mg/kg), and manganese (approximately 10-20 mg/kg), though these are not clinically meaningful at typical supplemental doses. Bioavailability of TSG is moderate, with animal studies suggesting oral bioavailability of approximately 20-35% with rapid hepatic metabolism; emodin undergoes extensive first-pass metabolism. Fat-soluble compounds such as resveratrol have improved absorption when taken with dietary fat.
Foti's primary bioactive compound TSG (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) inhibits NF-κB signaling pathways, reducing inflammatory cytokine production. The stilbene compounds also activate Nrf2 pathways, enhancing cellular antioxidant defense systems. Additionally, emodin and other anthraquinones may contribute to hepatoprotective effects through modulation of liver enzyme activity.
Human clinical evidence for foti remains limited, with most positive results coming from combination formulas rather than isolated foti studies. Small preliminary trials in hepatitis B patients showed potential liver function improvements, but sample sizes were under 100 participants. Animal studies demonstrate anti-atherosclerotic effects and improved lipid profiles, but these findings lack human validation. The majority of research consists of in vitro studies showing antioxidant activity, which cannot be directly extrapolated to human health outcomes.
Raw foti contains hepatotoxic compounds and has been linked to serious liver damage in multiple case reports. Processed foti (prepared with black bean liquid) reduces but does not eliminate hepatotoxicity risk. Foti may interact with warfarin and other blood thinners due to its coumarin content. Pregnant and breastfeeding women should avoid foti due to insufficient safety data and potential liver toxicity.
